The expression of PD-1 and LAG-3 has been shown to be up-regulated following the development of GC, which suggests that immunotherapy targeting PD-1 and LAG-3 represents a possible strategy for the treatment of GC (Takaya et al., 2015). Here, PDCD1 is linked to gastric cancer.